Mark Schiller - Kezar Life Chief Officer
| KZR Stock | USD 5.58 0.25 4.29% |
Executive
Mark Schiller is Chief Officer of Kezar Life Sciences
| Age | 45 |
| Phone | 650 822 5600 |
| Web | https://www.kezarlifesciences.com |
Mark Schiller Latest Insider Activity
Tracking and analyzing the buying and selling activities of Mark Schiller against Kezar Life stock is an integral part of due diligence when investing in Kezar Life. Mark Schiller insider activity provides valuable insight into whether Kezar Life is net buyers or sellers over its current business cycle. Note, Kezar Life insiders must abide by specific rules, including filing SEC forms every time they buy or sell Kezar Life'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Mark Schiller over two weeks ago Acquisition by Mark Schiller of 7200 shares of Kezar Life at 6.3 subject to Rule 16b-3 | ||
Mark Schiller over six months ago Disposition of 165000 shares by Mark Schiller of Kezar Life at 2.28 subject to Rule 16b-3 | ||
Mark Schiller over a year ago Kezar Life exotic insider transaction detected |
Kezar Life Management Efficiency
The company has Return on Asset of (0.2902) % which means that on every $100 spent on assets, it lost $0.2902. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.5472) %, meaning that it generated no profit with money invested by stockholders. Kezar Life's management efficiency ratios could be used to measure how well Kezar Life manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Stephen JD | Shattuck Labs | 50 | |
| Andrew Funderburk | Monte Rosa Therapeutics | N/A | |
| Robin Wagner | Keros Therapeutics | N/A | |
| Nathan Ihle | Bolt Biotherapeutics | N/A | |
| Mary Fenton | Cullinan Oncology LLC | 60 | |
| Ann Tomlin | Lyell Immunopharma | N/A | |
| Li Yang | Surrozen | 56 | |
| Jan Smith | Revolution Medicines | N/A | |
| Yung MD | Keros Therapeutics | 49 | |
| Cindy Berejikian | Mineralys Therapeutics, Common | N/A | |
| Greg Mann | Nkarta Inc | N/A | |
| Matthew JD | Lyell Immunopharma | 49 | |
| Christine JD | Nurix Therapeutics | 60 | |
| Alexander Constan | Ikena Oncology | N/A | |
| Edmund Dunn | Monte Rosa Therapeutics | 59 | |
| Saurabh Sewak | Foghorn Therapeutics | N/A | |
| Michael Naso | Century Therapeutics | N/A | |
| Magnus DPHIL | Monte Rosa Therapeutics | N/A | |
| John Berman | Larimar Therapeutics | N/A | |
| Rebecca Cohen | Ikena Oncology | N/A | |
| JD Esq | Kymera Therapeutics | 66 | |
Management Performance
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.29 |
Kezar Life Sciences Leadership Team
Elected by the shareholders, the Kezar Life's board of directors comprises two types of representatives: Kezar Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kezar. The board's role is to monitor Kezar Life's management team and ensure that shareholders' interests are well served. Kezar Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kezar Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joe Tedrick, Vice Resources | ||
| Christopher Kirk, Co-Founder, Chief Scientific Officer | ||
| Marc Belsky, CFO, Secretary | ||
| Noreen MD, Chief Officer | ||
| John Fowler, CoFounder Director | ||
| Pattie Chiang, Senior Controller | ||
| Michael Wolfe, Sr Operations | ||
| Jack Taunton, Co-Founder | ||
| Neel Anand, Senior Discovery | ||
| Zung To, Senior Development | ||
| Gitanjali Jain, Senior Affairs | ||
| PharmD Mordwinkin, Chief Strategy | ||
| Marc CPA, CFO Secretary | ||
| Mark Schiller, Chief Officer |
Kezar Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kezar Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | (88.94 M) | ||||
| Shares Outstanding | 7.3 M | ||||
| Shares Owned By Insiders | 11.99 % | ||||
| Shares Owned By Institutions | 62.00 % | ||||
| Number Of Shares Shorted | 120.6 K | ||||
| Price To Earning | (9.34) X | ||||
| Price To Book | 0.32 X | ||||
| Price To Sales | 6.12 X |
Pair Trading with Kezar Life
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kezar Life position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kezar Life will appreciate offsetting losses from the drop in the long position's value.Moving against Kezar Stock
| 0.47 | CPIX | Cumberland Pharmaceuticals | PairCorr |
| 0.43 | CMRX | Chimerix Sell-off Trend | PairCorr |
| 0.37 | FNA | Paragon 28 | PairCorr |
The ability to find closely correlated positions to Kezar Life could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kezar Life when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kezar Life - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kezar Life Sciences to buy it.
The correlation of Kezar Life is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kezar Life moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kezar Life Sciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kezar Life can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Kezar Stock Analysis
When running Kezar Life's price analysis, check to measure Kezar Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kezar Life is operating at the current time. Most of Kezar Life's value examination focuses on studying past and present price action to predict the probability of Kezar Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kezar Life's price. Additionally, you may evaluate how the addition of Kezar Life to your portfolios can decrease your overall portfolio volatility.